semaglutide for ckd FLOWing with the — NephJC Semaglutide significantly reduces risk of

Cynthia Maxwell MD, MBA, FRCSC, DABOM (Obesity Medicine), is the Medical Content Director of First Exposure, the Vice President, Medical Affairs & System Transformation and Lead Medical Executive at Womens College Hospital and Professor, Faculty of Medicine, Department of Obstetrics and Gynaecology and Division of Maternal Fetal Medicine at the University of Toronto

As a result, Medicaid coverage of GLP-1 drugs for obesity treatment is optional for states, while coverage for other indications (diabetes, cardiovascular disease, and sleep apnea) is required

Others report modest improvements in blood sugar or reduced cravings, but its often hard to tell which supplement or medication is responsible

We caught up with Mather, who participated in the game changer session The Risks and Rewards of GLP-1 Agonists Beyond Diabetes at the 2025 American Physiology Summit in April

Another important fact is that this L-DOPA is co-administered with carbidopa, another important dopamine-replacement therapy for PD, aiming to increase the bioavailability of the substance and prevent early conversion into dopamine prior to entering the brain (Gandhi and Saadabadi, 2025)